Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome

Prevention and Treatment With Calcifediol of COVID-19 Coronavirus-induced Acute Respiratory Syndrome (SARS)

The administration of Calcifediol in patients with COVID-19, will reduce the development of SARS and the worsening of the various phases of the syndrome. Reducing at least 25% in ICU admission and death from the process, reducing days of hospitalization, facilitating the recovery of the same, acting significantly and positively, in any of its phases throughout the natural history of illness. As a treatment with extensive experience of clinical use, safe, inexpensive, and potentially very effective, it will have a highly efficient cost-benefit impact on the prevention of SARS.

Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome

Recruitment

Summary

Participation Requirements

Description

Tracking Information